COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Intraoperative Radiation Therapy (IORT) in DCIS

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03216421
Recruitment Status : Recruiting
First Posted : July 13, 2017
Last Update Posted : October 22, 2020
Information provided by (Responsible Party):
Eileen Connolly, Columbia University

Brief Summary:
The goal of this study is to examine the role of Intraoperative Radiotherapy (IORT) in Ductal Carcinoma In-Situ (DCIS) and to improve the understanding of the clinical, radiographic, and patient-related impact of adopting IORT.

Condition or disease Intervention/treatment Phase
Breast Cancer Ductal Carcinoma in Situ Other: Quality of Life Questionnaires Not Applicable

Detailed Description:
With advances in technology and screening, the overdiagnosis and overtreatment of ductal carcinoma in situ (DCIS) have increased. Minimizing treatment toxicity and cost is a high priority area of research. Intraoperative Radiation Therapy (IORT)is a form of radiation where a single high dose of irradiation is applied to the tumor bed at the time of lumpectomy. Its use has not been previously studied in DCIS. Proposed advantages include decreased toxicity to adjacent tissue and organs, reduction in healthcare costs, and improved quality of life. The investigators hypothesize that IORT is a safe and patient-friendly alternative to whole breast irradiation.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 265 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Locoregional Breast Cancer Recurrence Following Targeted Intraoperative Radiotherapy (IORT) for Ductal Carcinoma in Situ (DCIS)
Actual Study Start Date : September 12, 2017
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : December 31, 2025

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Low/Intermediate Grade DCIS
Subjects with Low/Intermediate Grade DCIS will complete quality of life questionnaires before and after the IORT.
Other: Quality of Life Questionnaires
Quality of Life questionnaires will be completed by each subject.

High Grade DCIS
Subjects with High Grade DCIS will complete quality of life questionnaires before and after the IORT.
Other: Quality of Life Questionnaires
Quality of Life questionnaires will be completed by each subject.

Primary Outcome Measures :
  1. Rate of local recurrence [ Time Frame: 5 years ]
    Defined by ipsilateral breast tumor recurrence

Secondary Outcome Measures :
  1. Disease-free survival [ Time Frame: 5 years ]
    Determine incidence of any distant or local recurrence after the breast-conserving surgery (BCS) and IORT

  2. Overall survival [ Time Frame: 5 years ]
    Quantify the overall survival in women with DCIS following BCS and IORT at 5 years.

  3. Acute Toxicities associated with IORT [ Time Frame: 6 months ]
    Quantify the frequency of acute toxicities that occur within 6 months of having BCS and IORT. Measured using physician and patient reported toxicity surveys.

  4. Longterm radiation toxicity [ Time Frame: 5 years ]
    Quantify the frequency of toxicities that occur at greater than 6 months after having BCS and IORT. Measured using using physician and patient reported toxicity surveys as well as photographic assessment of cosmetic outcome.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Pathologically confirmed DCIS of the breast
  • Clinical ≤ 3.0 cm unifocal lesion
  • No clinical or pathological evidence of nodal involvement
  • Operable DCIS, suitable for breast conserving surgery
  • Plans to administer irradiation to the breast only
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-3, however grade 4 patients may be enrolled at the discretion of the treating radiation oncologist
  • Must have had a diagnostic mammogram or MRI performed within last 6 months
  • Women of child-bearing potential must have a negative pregnancy test in accordance to institutional guidelines
  • Women of child-bearing potential must agree to use adequate contraceptive precautions (defined as oral contraceptives, intrauterine devices, surgical contraceptives, or combination of condom and spermicide) from the time of negative pregnancy test through the radiation treatment period.
  • English or Spanish speaking
  • Able to sign informed consent
  • Amenable to regular follow-up (according to research policies) for at least 5 years.

Exclusion Criteria:

  • Histologic or clinical evidence of invasive breast cancer
  • Multicentric cancer in the ipsilateral breast as diagnosed by clinical examination, imaging, or pathologic assessment, not amenable to excision with negative margins with a single lumpectomy
  • Synchronous bilateral breast cancer at the time of diagnosis
  • Pathologic or imaging evidence of lymph node involvement
  • Any severe concomitant disease that may limit their life expectancy to less than 5 years.
  • Prior history of breast cancer or in-field radiation in the ipsilateral breast.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant or breast feeding women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03216421

Layout table for location contacts
Contact: Eileen Connolly, MD 212-305-5050
Contact: Mariamne Reyna 646-317-4244

Layout table for location information
United States, New York
Columbia University Medical Center Recruiting
New York, New York, United States, 10032
Contact: Eileen Connolly, MD    212-305-5050   
Contact: Mariamne Reyna    646-317-4244   
Sponsors and Collaborators
Columbia University
Layout table for investigator information
Principal Investigator: Eileen Connolly, MD Assistant Professor of Radiation Oncology
Layout table for additonal information
Responsible Party: Eileen Connolly, Assistant Professor, Columbia University Identifier: NCT03216421    
Other Study ID Numbers: AAAQ7853
First Posted: July 13, 2017    Key Record Dates
Last Update Posted: October 22, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Eileen Connolly, Columbia University:
Intraoperative Radiation (IORT)
Breast Conserving Surgery
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Carcinoma in Situ
Carcinoma, Ductal
Carcinoma, Intraductal, Noninfiltrating
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms by Site
Breast Diseases
Skin Diseases
Neoplasms, Ductal, Lobular, and Medullary
Breast Carcinoma In Situ